QualiLife Pharmaceuticals, Inc.
National institute accepts clinical trial of female sexual dysfunction treatment
Published in Elder Law Weekly, August 17th, 2005
This phase 3 type study will evaluate the efficacy and safety of Zestra compared to placebo oil in 200 women diagnosed with acquired mixed interest/desire/arousal/orgasm disorders in conditions of home use in conjunction with sexual activities. The Zestra study is the only registered study to directly address women's sexual problems.
The study is a randomized, placebo-controlled, double-blind, parallel design trial. Primary efficacy assessment will be the subjects' assessments of "successful and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
Source: Elder Law Weekly (2005-08-17)
More Articles from Elder Law Weekly
- Chinese Academy of Sciences
A new two-step method simplifies recombinant alpha-synuclein production - Sekhsaria Institute of Public Health, Maharashtra
Alcohol and tobacco use among middle-aged and elderly in Mumbai characterized - The Parkinson's Institute, Sunnyvale
Alpha-synuclein studied, intravesicular localization and exocytosis defined - Univ. of California, San Diego
Alpha-synuclein immunization may help in treating Lewy body disease - Aachen University of Technology
16-detector row CT is not suited for assessing all parameters - Alexion Pharmaceuticals, Inc.
Randomization completed for phase III TRIUMPH efficacy trial of Eculizumab - More from this issue of Elder Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
